Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mina Swiha

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
PET Clinics|April 26, 2024
Treatment Response Imaging in Prostate CancerMina Swiha, Andrei Gafita, Andrew Nguyen, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 18, 2026
Case - Radiation-induced sarcoma: A pitfall during PSMA-targeted radioligand therapyKhashayar Akbari-Kelachayeh, Amirfarhan Jafarinia, Mina Swiha, et al.
Seminars in Nuclear Medicine|August 9, 2023
How to Report PSMA PETMina Swiha, Narjess Ayati, Daniela E Oprea-Lager, et al.
AACE Clinical Case Reports|September 28, 2020
SEVERE HYPERCALCEMIA SECONDARY TO PARAFFIN OIL INJECTIONS IN A BODYBUILDER WITH SIGNIFICANT FINDINGS ON SCINTIGRAPHYParul Khanna, Alireza Khatami, Mina Swiha, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2024
Development of a Visually Calculated SUV<sub>mean</sub> (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to <sup>177</sup>Lu-PSMA Therapy: Comparison with Quantitative SUV<sub>mean</sub> and Patient OutcomesMina Swiha, Nathan Papa, Zahra Sabahi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Comparison of Posttherapy 4- and 24-Hour [<sup>177</sup>Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate CancerMina Swiha, Sarennya Pathmanandavel, Nathan Papa, et al.
Cancer Medicine|June 13, 2020
Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter DatabaseMohammed A Alghamdi, Carla P Amaro, Richard Lee-Ying, et al.
JACC. Cardiovascular Imaging|August 8, 2024
Risk Stratification in Cardiac Sarcoidosis With Cardiac Positron Emission Tomography: A Systematic Review and Meta-AnalysisTahir S Kafil, Omar M Shaikh, Yehia Fanous, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
Utility of <sup>64</sup>Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on <sup>68</sup>Ga-PSMA-11 PET/CTSherrington Li, Andrew Nguyen, William Counter, et al.
Nature Cancer|April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± <sup>177</sup>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trialLouise Emmett, Mina Swiha, Nathan Papa, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
PET Clinics|April 26, 2024
Treatment Response Imaging in Prostate CancerMina Swiha, Andrei Gafita, Andrew Nguyen, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 18, 2026
Case - Radiation-induced sarcoma: A pitfall during PSMA-targeted radioligand therapyKhashayar Akbari-Kelachayeh, Amirfarhan Jafarinia, Mina Swiha, et al.
Seminars in Nuclear Medicine|August 9, 2023
How to Report PSMA PETMina Swiha, Narjess Ayati, Daniela E Oprea-Lager, et al.
AACE Clinical Case Reports|September 28, 2020
SEVERE HYPERCALCEMIA SECONDARY TO PARAFFIN OIL INJECTIONS IN A BODYBUILDER WITH SIGNIFICANT FINDINGS ON SCINTIGRAPHYParul Khanna, Alireza Khatami, Mina Swiha, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2024
Development of a Visually Calculated SUV<sub>mean</sub> (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to <sup>177</sup>Lu-PSMA Therapy: Comparison with Quantitative SUV<sub>mean</sub> and Patient OutcomesMina Swiha, Nathan Papa, Zahra Sabahi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Comparison of Posttherapy 4- and 24-Hour [<sup>177</sup>Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate CancerMina Swiha, Sarennya Pathmanandavel, Nathan Papa, et al.
Cancer Medicine|June 13, 2020
Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter DatabaseMohammed A Alghamdi, Carla P Amaro, Richard Lee-Ying, et al.
JACC. Cardiovascular Imaging|August 8, 2024
Risk Stratification in Cardiac Sarcoidosis With Cardiac Positron Emission Tomography: A Systematic Review and Meta-AnalysisTahir S Kafil, Omar M Shaikh, Yehia Fanous, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
Utility of <sup>64</sup>Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on <sup>68</sup>Ga-PSMA-11 PET/CTSherrington Li, Andrew Nguyen, William Counter, et al.
Nature Cancer|April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± <sup>177</sup>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trialLouise Emmett, Mina Swiha, Nathan Papa, et al.
Pageof 2